LU90710I2 - Galanthamine ou ses sels d'addition acides - Google Patents

Galanthamine ou ses sels d'addition acides

Info

Publication number
LU90710I2
LU90710I2 LU90710C LU90710C LU90710I2 LU 90710 I2 LU90710 I2 LU 90710I2 LU 90710 C LU90710 C LU 90710C LU 90710 C LU90710 C LU 90710C LU 90710 I2 LU90710 I2 LU 90710I2
Authority
LU
Luxembourg
Prior art keywords
galanthamine
acid addition
addition salts
alzheimer
disease
Prior art date
Application number
LU90710C
Other languages
English (en)
Original Assignee
Synaptech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25227312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90710(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synaptech Inc filed Critical Synaptech Inc
Publication of LU90710I2 publication Critical patent/LU90710I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
LU90710C 1986-01-15 2001-01-03 Galanthamine ou ses sels d'addition acides LU90710I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/819,141 US4663318A (en) 1986-01-15 1986-01-15 Method of treating Alzheimer's disease

Publications (1)

Publication Number Publication Date
LU90710I2 true LU90710I2 (fr) 2001-03-05

Family

ID=25227312

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90710C LU90710I2 (fr) 1986-01-15 2001-01-03 Galanthamine ou ses sels d'addition acides

Country Status (10)

Country Link
US (1) US4663318A (fr)
EP (1) EP0236684B1 (fr)
JP (1) JPH08778B2 (fr)
AT (1) ATE76294T1 (fr)
AU (1) AU593051B2 (fr)
DE (3) DE10199020I2 (fr)
ES (1) ES2000428T3 (fr)
GR (2) GR880300077T1 (fr)
LU (1) LU90710I2 (fr)
NL (1) NL300140I2 (fr)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
WO1988008708A1 (fr) * 1987-05-04 1988-11-17 Bonnie Davis Composes permettant le traitement de la maladie d'alzheimer
IT1222395B (it) * 1987-07-30 1990-09-05 Pierrel Spa Composizione farmaceutica per somministrazione intranasale comprendente l'ormone ghrh,un agonista colinergico e/o un sale biliare
US4897388A (en) * 1988-12-20 1990-01-30 Geriatric Research Institute, Inc. Method of treating Alzheimer's disease
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
DK0584185T3 (da) * 1991-05-14 2000-02-07 Ernir Snorrason Behandling af træthedssyndrom med cholinesteraseinhibitorer
US5177070A (en) * 1991-11-15 1993-01-05 Ciba-Geigy Corporation Method of treating physiologic male erectile impotence
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
DE4301782C1 (de) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
US6316439B1 (en) 1993-10-15 2001-11-13 Aventis Pharamaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323196B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323195B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
PT787115E (pt) * 1994-10-21 2000-05-31 Sanochemia Pharmazeutika Ag Processos para a preparacao de derivados de 4a,5,9,10,11,12-hexa-hidro-6h-benzofuro¬3a,3,2-ef|¬2|benzazepina
US6407229B1 (en) 1994-10-21 2002-06-18 Sanochemia Pharmazeutika Ag Processes for the preparation of derivatives of 4a,5,9,10,11,12-hexahydro-6H-benzofuro-[3a,3,2-ef][2] benzazapine
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
AT402691B (de) * 1996-01-26 1997-07-25 Sanochemia Ltd Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
AU1738800A (en) 1998-11-23 2000-06-13 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
AU2004242546B2 (en) * 1998-11-23 2008-05-15 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
PL349501A1 (en) * 1998-12-24 2002-07-29 Janssen Pharmaceutica Nv Controlled release galantamine composition
US20050063998A1 (en) * 1999-10-26 2005-03-24 Francois Marc Karel Jozef Oral solution containing galantamine and a sweetening agent
DK1261345T3 (da) * 2000-01-28 2005-09-12 Tricia Grose Urtetilskud til kognitivt relateret svækkelse som fölge af östrogenmangel
US6426097B2 (en) 2000-01-28 2002-07-30 Herbaceuticals Inc. Herbal supplement for cognitive related impairment due to estrogen loss
DK1181294T3 (da) 2000-03-31 2004-08-02 Sanochemia Pharmazeutika Ag Hidtil ukendte derivater og analoger af galanthamin
CA2310990A1 (fr) 2000-04-03 2000-10-09 Michael Pontecorvo Utilisation de la galantamine pour le traitement de la maladie d'alzheimer; ciblage de la cause sous-jacente de la maladie
CA2310926C (fr) 2000-04-03 2002-10-15 Janssen Pharmaceutica N.V. Utilisation de la galantamine pour le traitement du comportement neuropsychiatrique associe a la maladie d'alzheimer
JP2003530437A (ja) * 2000-04-13 2003-10-14 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ Ａβ４２低下物質
JP4721386B2 (ja) * 2001-07-10 2011-07-13 第一三共株式会社 新規ガランタミン類縁体
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
IL165589A (en) 2002-06-14 2012-04-30 Toyama Chemical Co Ltd Pharmaceutical preparation to improve brain function and use
US20040067934A1 (en) * 2002-10-03 2004-04-08 Parys Wim Louis Julien Use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
WO2004037234A2 (fr) * 2002-10-24 2004-05-06 Merz Pharma Gmbh & Co. Kgaa Therapie combinee faisant appel a des derives de 1-aminocyclohexane ainsi qu'a des inhibiteurs d'acetylcholinesterase
US20040097484A1 (en) * 2002-11-14 2004-05-20 Marc Cantillion Once a day galantamine pharmaceutical compositions and methods of use
WO2004071431A2 (fr) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Composition et methode de traitement de troubles neurodegeneratifs
JP2007502332A (ja) * 2003-05-30 2007-02-08 マイクロバイア インコーポレイテッド 記憶および認知保護法
US20050048543A1 (en) * 2003-07-11 2005-03-03 Jeroen Aerssens CHRNA2 genetic markers associated with galantamine response
JP2007528857A (ja) * 2003-07-11 2007-10-18 ミリアド ジェネティクス， インコーポレイテッド アルツハイマー病の処置のための薬学的方法、投与レジメンおよび投薬形態
RU2357734C2 (ru) * 2003-07-25 2009-06-10 Ф.Хоффманн-Ля Рош Аг КОМБИНАЦИЯ АНТАГОНИСТА РЕЦЕПТОРА mGluR2 И ИНГИБИТОРА ФЕРМЕНТА AChE ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И/ИЛИ ХРОНИЧЕСКИХ НЕВРОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЙ
WO2005042762A2 (fr) * 2003-10-28 2005-05-12 Genaissance Pharmaceuticals, Inc. Marqueurs genetiques lrpap1 associes a la reponse a la galantamine
BG65658B1 (bg) * 2003-11-13 2009-05-29 "Софарма" Ад Комбиниран лекарствен продукт на основата на галантамин
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US7250258B2 (en) * 2003-12-15 2007-07-31 Pgxhealth Llc CDK5 genetic markers associated with galantamine response
CA2552114A1 (fr) * 2003-12-31 2005-07-21 Actavis Group Hf Formulations solides d'administration de galantamine
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
US20050252144A1 (en) * 2004-04-29 2005-11-17 Macdonald Robert A Veneers for walls, retaining walls and the like
EP1750724A4 (fr) * 2004-05-14 2008-01-23 Univ Johns Hopkins Methode pour ameliorer la fonction cognitive faisant appel a une co-administration d'un antagoniste du recepteur gabab et d'un inhibiteur d'acetylcholinesterase
US20080045500A1 (en) * 2004-07-01 2008-02-21 Eisai R&D Management Co., Ltd. Nerve Regeneration Stimulator
WO2006020853A2 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et methode de traitement de troubles neurodegeneratifs
WO2006020850A2 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
WO2006020852A2 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
WO2006056845A1 (fr) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc Derives d'acide 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoique comme inhibiteurs de hmg co-a reductase pour le traitement de l'hyperlipidemie
WO2006071274A2 (fr) * 2004-12-23 2006-07-06 Voyager Pharmaceutical Corporation Acetate de leuprolide et inhibiteurs de l'acetylcholinesterase ou antagonistes des recepteurs nmda pour le traitement de la maladie d'alzheimer
MX2007012374A (es) 2005-04-06 2008-02-22 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de condiciones relacionadas con cns.
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
AU2006272760A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
EP2046119A2 (fr) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Traitement de troubles psychiatriques
EP2420235A1 (fr) 2006-10-27 2012-02-22 Medivation Neurology, Inc. Procédés et polythérapies pour traiter la maladie d'Alzheimer
US20110201597A1 (en) 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
EP2271218B1 (fr) 2008-03-27 2017-05-24 Chase Pharmaceuticals Corporation Utilisation et composition permettant de traiter la démence
MX345236B (es) 2009-09-18 2017-01-23 Chase Pharmaceuticals Corp Metodo y composicion para tratar la demencia de tipo alzheimer.
EP2503996A2 (fr) 2009-11-26 2012-10-03 USV Limited Compositions pharmaceutiques à libération contrôlée de galantamine
AU2011215870B2 (en) 2010-02-09 2016-01-28 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2011151359A1 (fr) 2010-06-02 2011-12-08 Noscira, S.A. Traitement combiné comprenant un inhibiteur de la cholinestérase et un dérivé de thiadiazolidinedione
FR2962335B1 (fr) 2010-07-12 2013-01-18 Cll Pharma Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives
MX2015002864A (es) 2012-09-05 2015-07-14 Chase Pharmaceuticals Corp Composicion neuroprotectora anticolinergica y metodos.
WO2014078568A1 (fr) 2012-11-14 2014-05-22 The Johns Hopkins University Méthodes et compositions pour le traitement de la schizophrénie
BG66818B1 (bg) 2013-03-07 2019-01-31 Berbee Beheer B. V. Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки
CN105142623A (zh) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 用于改善认知功能的方法和组合物
EP3827820A1 (fr) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam pour améliorer la fonction cognitive
AU2014307803A1 (en) 2013-08-16 2016-03-10 Universiteit Maastricht Treatment of cognitive impairment with PDE4 inhibitor
CN112843005B (zh) 2015-05-22 2023-02-21 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物

Also Published As

Publication number Publication date
EP0236684A3 (en) 1988-12-14
ES2000428T9 (es) 2013-08-14
DE10199020I1 (de) 2001-05-23
AU593051B2 (en) 1990-02-01
DE3779149D1 (de) 1992-06-25
ES2000428T3 (es) 1993-10-01
AU6760987A (en) 1987-07-16
GR3005447T3 (fr) 1993-05-24
EP0236684B1 (fr) 1992-05-20
EP0236684A2 (fr) 1987-09-16
US4663318A (en) 1987-05-05
DE236684T1 (de) 1988-04-28
NL300140I2 (nl) 2004-04-01
JPH08778B2 (ja) 1996-01-10
ATE76294T1 (de) 1992-06-15
JPS62215527A (ja) 1987-09-22
GR880300077T1 (en) 1988-10-21
DE10199020I2 (de) 2004-05-06
NL300140I1 (nl) 2004-02-02
ES2000428A4 (es) 1988-03-01

Similar Documents

Publication Publication Date Title
LU90710I2 (fr) Galanthamine ou ses sels d'addition acides
DK549189D0 (da) Galanthamin-analoge samt anvendelse af disse til fremstilling af laegemidler til behandling af alzheimer's syge
NO902188L (no) Kateter med tilbakestroemnings-innsnevring.
DE3783068D1 (de) Medizinische vorrichtung.
DE19675046I2 (de) Pharmazeutische Verbindungen
DE68916693T2 (de) Molekular-Diagnose von Alzheimer-Krankheit.
IT8819213A0 (it) Procedimento e dispositivo per la realizzazione di mescole di caucciu'.
ATE78399T1 (de) Verwendung von buspiron zur verbesserung des kurzzeitgedaechtnisses.
KR890004737A (ko) 질병 치료용 자석
ATA19687A (de) Magnetischer wasseraufbereiter
MC1867A1 (fr) Verification d'identite
IT1217352B (it) Palizzata in calcestruzzo nonche'procedimento e dispositivo per laproduzione della stessa.
BE892069A (fr) Le 3', 4', 5'-trimethoxybenzoate de 17,18-deshydroapovincaminol et ses sels formes par addition avec des acides
FR2603284B1 (fr) Derives d'acide 7-oxabicyclo(2.2.1.)heptane hydroxamique a action therapeutique
FR2583419B1 (fr) Procede pour la preparation de 2-bromo-a-ergocryptine et ses sels d'addition d'acides.
IT1192097B (it) Dispositivo per l'introduzione delle pelli in macchine per conceria
IT8763326V0 (it) Presidio medico per l'elettromagnetoterapia.
FI871737A0 (fi) Kraftanlaeggning med foerbraenning i en fluidiserad baedd.
IT8619228A0 (it) Procedimento di trattamento dell'acqua.
IT8720208A0 (it) Macchina per l'impiego forestale destinata in particolare per la lavorazione di alberi.
DE68914886D1 (de) Mittel zur Behandlung von Raynaud's Krankheit.
FR2610519B1 (fr) Baignoire d'hydromassage
IT1221206B (it) Dispositivo d' abbronzatura
IT8601223A0 (it) Strumento indicatore del grado di abbronzatura dell'epidermide.
IT1216416B (it) Dispositivo per la sformatura di pali.